Drugs Approved by Health Canada for Kidney Cancer

Please note that access to these treatments differs according to your province. Please consult our detailed listing by province: Drug Access Chart by Province / Territory in Canada

Private prescription drug plans may cover some or all of the costs of these treatments.

 

Nexavar® (sorafenib):

http://www.nexavar.com (U.S. site)

Assistance Bayer Canada (ABC) NEXAVAR can help patients access insurance coverage and find other reimbursement sources for Nexavar. Patients and healthcare professionals can contact ABC NEXAVAR at 1.800.NEXAVAR (1.800.639.2827) for assistance.

For specific Product Monograph information and Patient Information relating to Health Canada approval of Nexavar, click here.

 

Sutent® (sunitinib):

http://www.sutent.com (U.S. site)

Pfizer's Oncology Patient Assistance Program is designed to simplify the insurance and reimbursement process for uninsured or underinsured patients. Healthcare professionals and patients can learn more about Pfizer's Oncology Patient Assitance Program by calling 1-844-616-6888.

For medical help relating to Sutent, Pfizer Canada operates a 1-800 number: the Med Info number is 1-800-463-6001

For specific Product Monograph information and Patient Information relating to Health Canada approval of Sutent for rcc, click here.

 

Torisel® (temsirolimus):

http://www.torisel.com (U.S. site)

A patient-friendly sheet about Torisel is available as a PDF download Torisel Patient Sheet April 2008

For specific Product Monograph information and Patient Information relating to Health Canada approval of Torisel for rcc, click here.

For information about access to Torisel contact the Pfizer's Oncology Patient Assistance Program at 1-844-616-6888.

 

Afinitor® (everolimus):

Afinitor was approved by Health Canada on December 14, 2009 for patients with metastatic rencal cell carcinoma who have previously been treated with targeted therapies, sunitinib or sorafenib.  If you feel that you would benefit from treatment with Afinitor*, please contact your treating physician. To inquire about the AfiniTRAC Patient Support Program call 1-888-623-4648.

 

Votrient® (pazopanib):

Votrient was approved by Health Canada in June 2010. To inquire about the Votrient In Reach Patient Support Program call 1-888-475-4255.

 

Inlyta® (axitinib):

On July 12, 2012 Health Canada approved axitinib (Inlyta) for the treatment of patients with metastatic renal cell carcinoma (RCC) of clear cell histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib. 

For specific Product Monograph information and Patient Information relating to Health Canada approval of Inlyta for rcc, click here.

Pfizer's Oncology Patient Assistance Program is designed to simplify the insurance and reimbursement process for uninsured or underinsured patients. Healthcare professionals and patients can learn more about Pfizer's Patient Assistance Program by calling 1-844-616-6888.

 

Opdivo® (nivolumab)

www.bmscanada.ca (Opdivo®)

In April, 2016, Health Canada approved Opdivo® (nivolumab) for the treatment of patients with advanced or metastatic renal cell carcinoma (mRCC). Opdivo® is the first immuno-oncology drug to be approved in Canada for kidney cancer. 

For specific Opdivo® Product Monograph information, click here and Patient information relating to the Health Canada approval of Opdivo® for mRCC, click here.

To inquire about Bristol-Myers Squibb’s Access to Hope program, a program to help cancer patients by supporting access to their treatment, call their toll-free number at 1-877-967-6626.